Atorvastatin affects TLR4 clustering via lipid raft modulation

International Immunopharmacology

Volumn 10, Issue 8, 2010, Pages 892-899

  Chansrichavala, Praveen ^a   Chantharaksri, Udom ^a   Sritara, Piyamitr ^b   Ngaosuwankul, Nathamon ^a   Chaiyaroj, Sansanee C ^a,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Chulabhorn Research Institute   (Thailand)

Author keywords

Atherosclerosis; Lipid raft; Mevalonate; Statins; Toll like receptor 4

Indexed keywords

ATORVASTATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MEVALONIC ACID; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; LIPID RAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, BLOCKING; CELL LINE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPOLYSACCHARIDES; MEMBRANE MICRODOMAINS; MEVALONIC ACID; MICE; PRECURSOR CELLS, B-LYMPHOID; PROTEIN TRANSPORT; PYRROLES; RECEPTOR AGGREGATION; TOLL-LIKE RECEPTOR 4;

EID: 77955012564     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.04.027     Document Type: Article

References (47)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
2. Sever P.S., Dahlof B., Poulter N.R., Wedel H., Beevers G., Caulfield M., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
3. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med. 2000, 6:1399-1402.
4. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., MÃ1/4ller M.R., Husslein P., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arteriosclerosis 2002, 22:1194-1199.
5. Ascer E., Bertolami M.C., Venturinelli M.L., Buccheri V., Souza J., Nicolau J.C., et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004, 177:161-166.
6. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 2001, 7:687-692.
7. Mach F. Immunosuppressive effects of statins. Atheroscler. Suppl. 2002, 3:17-20.
8. Ortego M., Bustos C., Hernandez-Presa M.A., Tunon J., Diaz C., Hernandez G., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147:253-261.
9. Hernandez-Presa M.A., Ortego M., Tunon J., Martin-Ventura J.L., Mas S., Blanco-Colio L.M., et al. Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet. Cardiovasc. Res. 2003, 57:168-177.
10. Wang H.R., Li J.J., Huang C.X., Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin. Chim. Acta 2005, 353:53-60.
11. Xu X.H., Shah P.K., Faure E., Equils O., Thomas L., Fishbein M.C., et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001, 104:3103-3108.
12. Kiechl S., Lorenz E., Reindl M., Wiedermann C.J., Oberhollenzer F., Bonora E., et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J. Med. 2002, 347:185-192.
13. Foldes G., von Haehling S., Okonko D.O., Jankowska E.A., Poole-Wilson P.A., Anker S.D. Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. Int. J. Cardiol. 2008, 124:80-85.
14. Methe H., Kim J.O., Kofler S., Weis M., Nabauer M., Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005, 111:2654-2661.
15. Bjorkbacka H., Kunjathoor V.V., Moore K.J., Koehn S., Ordija C.M., Lee M.A., et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 2004, 10:416-421.
16. Chansrichavala P., Chantharaksri U., Sritara P., Chaiyaroj S. Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. Asian Pac. J. Allergy Immunol. 2009, 27:49-57.
17. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
18. Cheng P.C., Cherukuri A., Dykstra M., Malapati S., Sproul T., Chen M.R., et al. Floating the raft hypothesis: the roles of lipid rafts in B cell antigen receptor function. Semin. Immunol. 2001, 13:107-114.
19. Cherukuri A., Dykstra M., Pierce S.K. Floating the raft hypothesis: lipid rafts play a role in immune cell activation. Immunity 2001, 14:657-660.
20. Triantafilou M., Miyake K., Golenbock D.T., Triantafilou K. Mediators of innate immune recognition of bacteria concentrate in lipid rafts and facilitate lipopolysaccharide-induced cell activation. J. Cell Sci. 2002, 115:2603-2611.
21. Akashi S., Shimazu R., Ogata H., Nagai Y., Takeda K., Kimoto M., et al. Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J. Immunol. 2000, 164:3471-3475.
22. Kawasaki K., Akashi S., Shimazu R., Yoshida T., Miyake K., Nishijima M. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J. Biol. Chem. 2000, 275:2251-2254.
23. Okamoto M., Oh E.G., Oshikawa T., Furuichi S., Tano T., Ahmed S.U., et al. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant. Clin. Diagn. Lab. Immunol. 2004, 11:483-495.
24. Mantuano E., Santi S., Filippi C., Manca-Rizza G., Paoletti S., Consani C., et al. Simvastatin and fluvastatin reduce interleukin-6 and interleukin-8 lipopolysaccharide (LPS) stimulated production by isolated human monocytes from chronic kidney disease patients. Biomed. Pharmacother. 2007, 61:360-365.
25. Akdim F., van Leuven S.I., Kastelein J.J., Stroes E.S. Pleiotropic effects of statins: stabilization of the vulnerable atherosclerotic plaque?. Curr. Pharm. Des. 2007, 13:1003-1012.
26. Gomez-Hernandez A., Sanchez-Galan E., Martin-Ventura J.L., Vidal C., Blanco-Colio L.M., Ortego M., et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J. Cardiovasc. Pharmacol. 2006, 47:60-69.
27. Johnson J.L., Jackson C.L., Angelini G.D., George S.J. Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1707-1715.
28. Yilmaz A., Lochno M., Traeg F., Cicha I., Reiss C., Stumpf C., et al. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 2004, 176:101-110.
29. Endres M., Laufs U., Huang Z., Nakamura T., Huang P., Moskowitz M.A., et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA 1998, 95:8880-8885.
30. Hernandez-Perera O., Sanchez-Pascuala R., Hernandez G. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 1998, 101:2711-2719.
31. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
32. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78-84.
33. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J. Med. 1995, 333:621-627.
34. Aktas O., Waiczies S., Smorodchenko A., Dorr J., Seeger B., Prozorovski T., et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 2003, 197:725-733.
35. Hansson G.K., Robertson A.K., Soderberg-Naucler C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 2006, 1:297-329.
36. Laberge M.A., Moore K.J., Freeman M.W. Atherosclerosis and innate immune signaling. Ann. Med. 2005, 37:130-140.
37. Reiss A.B., Glass A.D. Atherosclerosis: immune and inflammatory aspects. J. Investig. Med. 2006, 54:123-131.
38. Stoll G., Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006, 37:1923-1932.
39. Yilmaz A., Reiss C., Tantawi O., Weng A., Stumpf C., Raaz D., et al. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004, 172:85-93.
40. Yilmaz A., Reiss C., Weng A., Cicha I., Stumpf C., Steinkasserer A., et al. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J. Leukoc. Biol. 2006, 79:529-538.
41. Niessner A., Steiner S., Speidl W.S., Pleiner J., Seidinger D., Maurer G., et al. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006, 189:408-413.
42. Methe H., Kim J.O., Kofler S., Nabauer M., Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1439-1445.
43. Jury E.C., Isenberg D.A., Mauri C., Ehrenstein M.R. Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. J. Immunol. 2006, 177:7416-7422.
44. Dai Q., Pruett S.B. Ethanol suppresses LPS-induced Toll-like receptor 4 clustering, reorganization of the actin cytoskeleton, and associated TNF-alpha production. Alcohol. Clin. Exp. Res. 2006, 30:1436-1444.
45. Hillyard D.Z., Cameron A.J., McDonald K.J., Thomson J., MacIntyre A., Shiels P.G., et al. Simvastatin inhibits lymphocyte function in normal subjects and patients with cardiovascular disease. Atherosclerosis 2004, 175:305-313.
46. Hillyard D.Z., Jardine A.G., McDonald K.J., Cameron A.J. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. Atherosclerosis 2004, 172:219-228.
47. Hillyard D.Z., Nutt C.D., Thomson J., McDonald K.J., Wan R.K., Cameron A.J., et al. Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis 2007, 191:319-325.